TIDM0A45
Moderna Inc
20 December 2022
Chantal Friebertshäuser Joins Moderna as Senior Vice President,
Commercial
Newly created role will have responsibility for commercial
efforts in Europe, Middle East and Canada
CAMBRIDGE, MA / ACCESSWIRE / December 20, 2022 / Moderna, Inc.
(NASDAQ:MRNA), a biotechnology company pioneering messenger RNA
(mRNA) therapeutics and vaccines, today announced the appointment
of Chantal Friebertshäuser as Senior Vice President, Commercial,
Europe, Middle East and Canada effective January 1, 2023. Ms.
Friebertshäuser will be responsible for commercial efforts in
Europe, Middle East and Canada, reporting to Arpa Garay, Moderna's
Chief Commercial Officer.
"Chantal has extensive experience in leading global teams and
scaling commercial organizations regionally," said Arpa Garay,
Moderna's Chief Commercial Officer. "Her insights, drive and
commitment to patients will be instrumental as we enter new markets
and advance our platform-based approach to medicine. Having worked
with her previously, I know first-hand that she will be a terrific
addition to the organization."
Ms. Friebertshäuser joins Moderna from Merck Sharp & Dohme
(MSD), where she served in a variety of in-market and global
commercial leadership roles across 15 years, including her most
recent position of Human Health Senior Vice President and Managing
Director at MSD Germany. In this role, Ms. Friebertshäuser was
responsible for the company's Human Health Organization and also
led the MSD Country Council which convened leaders from the
organization's Human Health, Animal Health, Research and
Manufacturing sites. Other prior roles include German Business Unit
Leader, Global Market Access Leader, Managing Director of Austria
and Global Commercial Lead for the company's HPV vaccine franchise.
Prior to MSD, Ms. Friebertshäuser spent 10 years in various roles
at Eli Lilly.
"Over the course of my career, I've always had a deep passion
for bringing forward business solutions that improve lives, while
also building diverse teams unified by a common, impactful
mission," said Ms. Friebertshäuser. "I am thrilled to join Moderna
and the mission to transform medicine - and the world - through the
promise of mRNA and look forward to expanding its presence in
Europe, Middle-East and Canada."
Ms. Friebertshäuser holds a Master of Arts in International
Business from the School of Business ESC in Rennes, France. She
will be based in Switzerland.
About Moderna
In over 10 years since its inception, Moderna has transformed
from a research-stage company advancing programs in the field of
messenger RNA (mRNA), to an enterprise with a diverse clinical
portfolio of vaccines and therapeutics across seven modalities, a
broad intellectual property portfolio in areas including mRNA and
lipid nanoparticle formulation, and an integrated manufacturing
plant that allows for both clinical and commercial production at
scale. Moderna maintains alliances with a broad range of domestic
and overseas government and commercial collaborators. Most
recently, Moderna's capabilities have come together to allow the
authorized use and approval of one of the earliest and most
effective vaccines against the COVID-19 pandemic.
Moderna's mRNA platform builds on continuous advances in basic
and applied mRNA science, delivery technology and manufacturing,
and has allowed the development of therapeutics and vaccines for
infectious diseases, immuno-oncology, rare diseases, cardiovascular
diseases, and autoimmune diseases. Moderna has been named a top
biopharmaceutical employer by Science for the past eight years. To
learn more, visit www.modernatx.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including regarding: the hiring of Chantal
Friebertshäuser as Senior Vice President, Commercial, Europe,
Middle East and Canada for Moderna. The forward-looking statements
in this press release are neither promises nor guarantees, and you
should not place undue reliance on these forward-looking statements
because they involve known and unknown risks, uncertainties, and
other factors, many of which are beyond Moderna's control and which
could cause actual results to differ materially from those
expressed or implied by these forward-looking statements. These
risks, uncertainties, and other factors include those other risks
and uncertainties described under the heading "Risk Factors" in
Moderna's most recent Annual Report on Form 10-K and the Quarterly
Report on Form 10-Q for the quarter ended March 31, 2022, each
filed with the U.S. Securities and Exchange Commission (SEC) and in
subsequent filings made by Moderna with the SEC, which are
available on the SEC's website at www.sec.gov. Except as required
by law, Moderna disclaims any intention or responsibility for
updating or revising any forward-looking statements contained in
this press release in the event of new information, future
developments or otherwise. These forward-looking statements are
based on Moderna's current expectations and speak only as of the
date of this press release.
Moderna Contacts
Media:
Luke Mircea Willats
Director, Corporate Communications
Luke.Mirceawillats@modernatx.com
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAPPGRCPUPPGPU
(END) Dow Jones Newswires
December 20, 2022 07:51 ET (12:51 GMT)
Moderna (LSE:0A45)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Moderna (LSE:0A45)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024